AZN Stock Overview
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide.
+ 1 more risk
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£82.76|
|52 Week High||UK£95.23|
|52 Week Low||UK£67.36|
|1 Month Change||-9.00%|
|3 Month Change||-2.82%|
|1 Year Change||6.10%|
|3 Year Change||33.25%|
|5 Year Change||104.98%|
|Change since IPO||1,146.39%|
Recent News & Updates
Is AstraZeneca (LON:AZN) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
|AZN||GB Pharmaceuticals||GB Market|
Return vs Industry: AZN underperformed the UK Pharmaceuticals industry which returned 9.2% over the past year.
Return vs Market: AZN underperformed the UK Market which returned 13.8% over the past year.
|AZN Average Weekly Movement||4.0%|
|Pharmaceuticals Industry Average Movement||5.7%|
|Market Average Movement||4.9%|
|10% most volatile stocks in GB Market||9.8%|
|10% least volatile stocks in GB Market||2.5%|
Stable Share Price: AZN is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: AZN's weekly volatility (4%) has been stable over the past year.
About the Company
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company’s marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca.
AstraZeneca Fundamentals Summary
|AZN fundamental statistics|
Is AZN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AZN income statement (TTM)|
|Cost of Revenue||US$9.06b|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Feb 10, 2022
|Earnings per share (EPS)||0.95|
|Net Profit Margin||4.48%|
How did AZN perform over the long term?See historical performance and comparison
2.6%Current Dividend Yield
Is AstraZeneca undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AZN (£82.76) is trading below our estimate of fair value (£193.07)
Significantly Below Fair Value: AZN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AZN is poor value based on its PE Ratio (115.4x) compared to the UK Pharmaceuticals industry average (29.7x).
PE vs Market: AZN is poor value based on its PE Ratio (115.4x) compared to the UK market (19x).
Price to Earnings Growth Ratio
PEG Ratio: AZN is poor value based on its PEG Ratio (3.7x)
Price to Book Ratio
PB vs Industry: AZN is good value based on its PB Ratio (4.3x) compared to the GB Pharmaceuticals industry average (4.5x).
How is AstraZeneca forecast to perform in the next 1 to 3 years based on estimates from 22 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AZN's forecast earnings growth (31.6% per year) is above the savings rate (0.9%).
Earnings vs Market: AZN's earnings (31.6% per year) are forecast to grow faster than the UK market (12.6% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: AZN's revenue (10.4% per year) is forecast to grow faster than the UK market (4.9% per year).
High Growth Revenue: AZN's revenue (10.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AZN's Return on Equity is forecast to be very high in 3 years time (68.8%).
How has AstraZeneca performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AZN has a large one-off loss of $417.0M impacting its September 30 2021 financial results.
Growing Profit Margin: AZN's current net profit margins (4.5%) are lower than last year (9.7%).
Past Earnings Growth Analysis
Earnings Trend: AZN's earnings have declined by 5.4% per year over the past 5 years.
Accelerating Growth: AZN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: AZN had negative earnings growth (-41.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-20.6%).
Return on Equity
High ROE: AZN's Return on Equity (3.7%) is considered low.
How is AstraZeneca's financial position?
Financial Position Analysis
Short Term Liabilities: AZN's short term assets ($26.7B) exceed its short term liabilities ($23.6B).
Long Term Liabilities: AZN's short term assets ($26.7B) do not cover its long term liabilities ($43.7B).
Debt to Equity History and Analysis
Debt Level: AZN's net debt to equity ratio (65.8%) is considered high.
Reducing Debt: AZN's debt to equity ratio has reduced from 118.1% to 83.7% over the past 5 years.
Debt Coverage: AZN's debt is not well covered by operating cash flow (19%).
Interest Coverage: AZN's interest payments on its debt are well covered by EBIT (4.7x coverage).
What is AstraZeneca current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: AZN's dividend (2.56%) is higher than the bottom 25% of dividend payers in the UK market (1.37%).
High Dividend: AZN's dividend (2.56%) is low compared to the top 25% of dividend payers in the UK market (4.17%).
Stability and Growth of Payments
Stable Dividend: AZN's dividends per share have been stable in the past 10 years.
Growing Dividend: AZN's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (341.7%), AZN's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: AZN's dividends in 3 years are forecast to be well covered by earnings (34.4% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Pascal Soriot (62 yo)
Mr. Pascal Soriot, M.B.A., D.V.M., serves as Director at Acerta Pharma B.V. He joined Acerta Pharma in January 2018 as Vice President Research Europe & Site Head of Acerta’s R&D site in The Netherlands. Dr...
CEO Compensation Analysis
Compensation vs Market: Pascal's total compensation ($USD21.09M) is above average for companies of similar size in the UK market ($USD3.65M).
Compensation vs Earnings: Pascal's compensation has been consistent with company performance over the past year.
Experienced Management: AZN's management team is seasoned and experienced (8.8 years average tenure).
Experienced Board: AZN's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18%.
AstraZeneca PLC's employee growth, exchange listings and data sources
- Name: AstraZeneca PLC
- Ticker: AZN
- Exchange: LSE
- Founded: 1992
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£128.207b
- Shares outstanding: 1.55b
- Website: https://www.astrazeneca.com
Number of Employees
- AstraZeneca PLC
- 1 Francis Crick Avenue
- Cambridge Biomedical Campus
- CB2 0AA
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/30 21:35|
|End of Day Share Price||2021/11/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.